These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 8842344)

  • 1. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis.
    Kretschmar M; Nichterlein T; Hannak D; Hof H
    Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes).
    Kretschmar M; Amselem S; Zawoznik E; Mosbach K; Dietz A; Hof H; Nichterlein T
    Mycoses; 2001; 44(7-8):281-6. PubMed ID: 11714063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system.
    Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ
    J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
    Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
    J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
    Andes D; Safdar N; Marchillo K; Conklin R
    Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
    Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
    J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High purity amphotericin B.
    Cleary JD; Chapman SW; Swiatlo E; Kramer R
    J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
    Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
    Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
    Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Emulsion of amphotericin B in Intralipid 20%: in vitro and in vivo efficacy].
    Chavanet P; Charlier N; Brenet A; Goux A; Muggéo E; Caillot D; Casasnovas O; Kistermann JP; Waldner A; Portier H
    Pathol Biol (Paris); 1992 May; 40(5):507-12. PubMed ID: 1495835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
    Chakraborty KK; Naik SR
    J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis.
    Adler-Moore JP; Olson JA; Proffitt RT
    J Antimicrob Chemother; 2004 Dec; 54(6):1096-102. PubMed ID: 15509617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacies of amphotericin B (AMB) lipid complex, AMB colloidal dispersion, liposomal AMB, and conventional AMB in treatment of murine coccidioidomycosis.
    González GM; Tijerina R; Najvar LK; Bocanegra R; Rinaldi MG; Graybill JR
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2140-3. PubMed ID: 15155212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
    Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
    Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice.
    van Etten EW; ten Kate MT; Stearne LE; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 1995 Sep; 39(9):1954-8. PubMed ID: 8540697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans.
    An M; Shen H; Cao Y; Zhang J; Cai Y; Wang R; Jiang Y
    Int J Antimicrob Agents; 2009 Mar; 33(3):258-63. PubMed ID: 19095412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.
    Louie A; Kaw P; Banerjee P; Liu W; Chen G; Miller MH
    Antimicrob Agents Chemother; 2001 Feb; 45(2):485-94. PubMed ID: 11158745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.